ARROWHEAD PHARMACEUTICALS INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
ARROWHEAD PHARMACEUTICALS INC. - More news...
ARROWHEAD PHARMACEUTICALS INC. - More news...
- Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
- Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
- Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrowhead Pharmaceuticals, Inc. - ARWR
- Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
- Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrowhead Pharmaceuticals, Inc. - ARWR
- Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation
- Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
- Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
- Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
- Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
- Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
- Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
- Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
- Arrowhead Announces JNJ-75220795 in Development for NASH
- Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
- Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
- Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
- Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
- Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results
- Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
- Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
- Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
- Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
